Financials data is unavailable for this security.
View more
Year on year Kyorin Pharmaceutical Co Ltd grew net income 12.68% from 4.72bn to 5.32bn primarily through revenue growth (113.27bn to 119.53bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the 5.53% growth in revenues contributed enough to still see net income improve.
Gross margin | 42.90% |
---|---|
Net profit margin | 4.60% |
Operating margin | 4.91% |
Return on assets | 3.14% |
---|---|
Return on equity | 4.34% |
Return on investment | 4.07% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at Kyorin Pharmaceutical Co Ltd fell by 4.93bn. However, the company earned 1.52bn from its operations for a Cash Flow Margin of 1.27%. In addition the company used 3.19bn on investing activities and also paid 3.35bn in financing cash flows.
Cash flow per share | 172.48 |
---|---|
Price/Cash flow per share | 9.86 |
Book value per share | 2,263.71 |
---|---|
Tangible book value per share | 2,173.33 |
More ▼
Balance sheet in JPYView more
Current ratio | 2.48 |
---|---|
Quick ratio | 1.30 |
Total debt/total equity | 0.1591 |
---|---|
Total debt/total capital | 0.1372 |
More ▼
Growth rates in JPY
SmartText is unavailable
Div yield(5 year avg) | 3.23% |
---|---|
Div growth rate (5 year) | -7.06% |
Payout ratio (TTM) | 54.68% |
EPS growth(5 years) | -2.39 |
---|---|
EPS (TTM) vs TTM 1 year ago | 27.45 |
More ▼